Status:
WITHDRAWN
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed malignant melanoma
- Stage III (unresectable) or Stage IV disease which may have been treated with up to one prior cytotoxic chemotherapy and/or up to 3 other therapeutic regimens
- Willing to undergo up to 3 biopsies of an accessible lesion
Exclusion
- Active/symptomatic brain metastases
- Primary ocular melanoma or primary tumor of unknown origin
- Concurrent autoimmune disease
- Previous treatment with a CD137 agonist or CTLA-4 inhibitor
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00803374
Start Date
November 1 2010
End Date
January 1 2013
Last Update
November 21 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Los Angeles, California, United States, 90025
2
Local Institution
New Haven, Connecticut, United States, 06520
3
Local Institution
Tampa, Florida, United States, 33612
4
Local Institution
Boston, Massachusetts, United States, 02114